GW501516 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Agathe Niehus, born on 28 December 1904 Gret Baumann, born on 8 February 1906 Franz Jung-Merker, born on 28 November 1908 Marianne Niehus, born on 20 September 1910 Helene Hoerni, born on 18 March 1914 None of the children continued in their father's field. The daughters, Agathe and Marianne, assisted in publishing work. During his marriage, Jung engaged in at least one extramarital relationship: with his patient and, later, fellow psychoanalyst Sabina Spielrein. A continuing affair with Toni Wolff, starting in 1910, has also been alleged. Jung confided in Freud that he had "'polygamous components' in himself" and that "'The pre-requisite of a good marriage, it seems to me, is the licence to be unfaithful'".
The photosynthetic amoeboids in the genus Paulinella—P. chromatophora, P. micropora, and marine P. longichromatophora—have the only known independently evolved chloroplast, often called a chromatophore. While all other chloroplasts originate from a single ancient endosymbiotic event, Paulinella independently acquired an endosymbiotic cyanobacterium from the genus Synechococcus around 90 – 140 million years ago. Each Paulinella cell contains one or two sausage-shaped chloroplasts; they were first described in 1894 by German biologist Robert Lauterborn. The chromatophore is highly reduced compared to its free-living cyanobacterial relatives and has limited functions. For example, it has a genome of about 1 million base pairs, one third the size of Synechococcus genomes, and only encodes around 850 proteins. However, this is still much larger than other chloroplast genomes, which are typically around 150,000 base pairs. Chromatophores have also transferred much less of their DNA to the nucleus of their hosts. About 0.3–0.8% of the nuclear DNA in Paulinella is from the chromatophore, compared with 11–14% from the chloroplast in plants. Similar to other chloroplasts, Paulinella provides specific proteins to the chromatophore using a specific targeting sequence. Because chromatophores are much younger compared to the canonical chloroplasts, Paulinella chromatophora is studied to understand how early chloroplasts evolved.
Documentaries are informative at times, and certain types are often used within schools as a resource to teach various principles. Documentary filmmakers have a responsibility to be truthful to their vision of the world without intentionally misrepresenting a topic. Social media organizations, such as Dailymotion and YouTube, with many of these platforms receiving popular interest, have provided an avenue for the growth of documentaries as a particular film genre. Such platforms have increased the distribution area and ease of accessibility, given the ability of online video sharing to spread to multiple audiences at once as well as to work past certain socio-political hurdles such as censorship.
Sources: en.wikipedia.org
One of those was the idea that when introducing a new mechanic, the level was designed to teach the new mechanic without potential harm to the player-character, followed by then testing that mechanic in a more harmful situation to the character. The team also included a brief mention to the long-fall boots from Aperture Science from the Portal series; Portal had come out after Half-Life 2 but loosely tied narratively to the Half-Life universe, and the team felt it appropriate to show the competing lab's technology within the Black Mesa facility from this connection. Once the team had gotten all but the Xen levels completed in the new Source engine they were content with, they released these on Steam's early access on May 5, 2015, to get feedback and bug testing, stating that the Xen sections were still a work in progress. This version also included the deathmatch multiplayer modes with some of Half-Life's remade maps. Early access also brought Crowbar Collective additional support from developers and artists to help with finalizing the project.
== Early life and education == Born in Shawinigan, Quebec. He is the brother of Jean Chrétien, who was Prime Minister of Canada from 1993 to 2003. He received a Bachelor of Arts degree from the Séminaire de Joliette in 1955, a M.D. from the Université de Montréal in 1960, and a Master of Science in Experimental Medicine from McGill University in 1962. He did post-graduate studies from 1962 to 1964 at Harvard University and from 1964 to 1967 at the University of California, Berkeley and University of California, San Francisco.
11 January 1919: The Germans recapture Sarnowa and win in Battle of Zbąszyń; Polish victory in Battle of Szubin and capture Łabiszyn, Złotniki and Żnin. 12 January 1919: fighting near Leszno and Lipno. 13 January 1919: The Germans recapture Szamocin. 14 January 1919: The Commission of the NRL appeals to Roman Dmowski for help negotiate a ceasefire. 15 January 1919: failed attempt to recapture Szamocin by Poles. 16 January 1919 The first number of Tygodnik Urzędowy Naczelnej Rady Ludowej, with the laws of the NRL, is published. The Polish government of Ignacy Paderewski has two politicians of Greater Poland: Józef Englich, the minister of treasury, and Kazimierz Hącia, the minister of industry and trade. 17 January 1919: Men born in 1897, 1898, and 1899 are called up and drafted into Great Polish Army. 20 January 1919: the transfer of money to banks of Germany on the other side of the front line is forbidden. 21 January 1919 NRL creates oath of soldiers of Great Polish Army. 22 January 1919 Northern front: Poles are forced to leave Potulice. Southern front: Poles win the Battle of Robaczysko. Joseph Noulens is nominated by Supreme Council of Allied Countries as chief of Allied mission in Poland. 23 January 1919: Poles defend Miejska Górka after heavy fighting. 25 January 1919 Poles capture Babimost and Kargowa. All communication between Greater Poland and Germany is broken. Decree cancels Prussian prohibition of Polish language in schools.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.